Possibilities of medicines provision for ethiotropic therapy to outpatients with COVID-19
https://doi.org/10.34680/2076-8052.2021.3(124).78-81
Abstract
Due to the high morbidity and mortality rate, as well as the rapid spread of infection, COVID-19 is one of the most discussed topics in everyday life and the health care sphere. Etiotropic therapy is an important component of the treatment COVID-19 patients. According to temporary guidelines for the prevention, diagnosis and treatment of COVID-19, outpatient therapy of this disease is allowed. The priority scheme of medical treatment includes favipiravir. Favipiravir drugs entered the Russian pharmaceutical market relatively recently. At present four trade names have been registered. Various forms and packaging, range and price characteristics of favipiravir are analysed in the article.
About the Authors
E. S. Egorova
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
A. В. Yershevskaya
Новгородский государственный университет имени Ярослава Мудрого
Russian Federation
Russian Federation
References
1. Nagibin O.A. Problemy obespecheniya neobkhodimymi lekarstvennymi preparatami otdel'nykh kategoriy grazhdan, imeyushchikh pravo na mery sotsial'noy podderzhki [Problems of providing certain categories of citizens entitled to social support measures with the essential drugs]. Ural'skiy meditsinskiy zhurnal, 2019, no. 9 (177), pp. 137-141.
2. Ministerstvo zdravoohraneniya Rossijskoj Federacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Vremennye metodicheskie rekomendacii (versiya 10 ot 08.02.2021) [Ministry of Public Health of Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines (version 10 dated 08.02.20201)]. Moscow, MZ RF Publ., 2021, 262 p.
3. Ruzhentsova T.A., Chukhlyaev P.V., Khavkina D.A. et al. Vozmozhnosti etiotropnoy terapii koronavirusnoy infektsii, vyzvannoy SARS-CoV-2, u ambulatornykh patsientov [Potential for etiotropic therapy of SARS-CoV2-induced coronavirus disease in outpatients]. Meditsinskiy opponent, 2020, no.1(9), pp.48-58.
4. Balykova L.A., Pavelkina V.F., Shmyreva N.V. i dr. Sravnitel'naya effektivnost' i bezopasnost' razlichnykh skhem etiotropnoy terapii u patsientov s novoy koronavirusnoy infektsiey (COVID-19) [Comparative efficacy and safety of various etiotropic therapy regimens in patients with a new coronavirus infection (COVID-19)]. Farmatsiya i farmakologiya, 2020, vol. 8, no. 3, pp.150-159.
5. Reshenie FAS Rossii ot 15 oktyabrya 2020 goda «O soglasovanii predel'nykh otpusknykh tsen proizvoditeley na lekarstvennye preparaty, vklyuchennye v perechen' zhiznenno neobkhodimykh i vazhneyshikh lekarstvennykh preparatov» [Decision of FAS Russia of 15 October 2020 “On agreement of ex-works maximum sale prices for medicines included into the list of vital and essential drugs”].
Review
For citations:
Egorova E.S., Yershevskaya A.В. Possibilities of medicines provision for ethiotropic therapy to outpatients with COVID-19. Title in english. 2021;(3(124)):78-81. (In Russ.) https://doi.org/10.34680/2076-8052.2021.3(124).78-81
Views:
58
Email this article 